Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy

NCT03713294 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03713294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03713294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2019
Completion date
November 14, 2024
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory plasma cell myeloma